Lava Therapeutics N.V. (LVTX)

$1.31 +0.08 (6.50%)
Market Cap 29.99M
Revenue (ttm) 11.98M
Net Income (ttm) -25.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -209.60%
Debt to Equity Ratio 0.18
Volume 102,000
Avg Vol 503,274
Day's Range N/A - N/A
Shares Out 26.31M
Stochastic %K 88%
Beta 0.46
Analysts Sell
Price Target $1.83

Latest News on LVTX

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

Apr 16, 2025, 7:30 AM EDT - 3 days ago

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 28, 2025, 7:30 AM EDT - 22 days ago

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

Feb 28, 2025, 12:32 PM EST - 7 weeks ago

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

Jan 10, 2025, 8:23 AM EST - 3 months ago

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Dec 10, 2024, 7:30 AM EST - 4 months ago

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 8 months ago

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LAVA Reports Second Quarter 2024 Financial Results and Business Update

Aug 20, 2024, 7:30 AM EDT - 8 months ago

LAVA Reports Second Quarter 2024 Financial Results and Business Update

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 20, 2024, 7:30 AM EDT - 10 months ago

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

LAVA Announces Annual Meeting of Shareholders

Jun 10, 2024, 7:00 AM EDT - 11 months ago

LAVA Announces Annual Meeting of Shareholders

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 7:00 AM EDT - 11 months ago

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

May 21, 2024, 7:00 AM EDT - 11 months ago

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

May 6, 2024, 4:05 PM EDT - 1 year ago

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

Mar 20, 2024, 7:00 AM EDT - 1 year ago

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

Mar 5, 2024, 7:30 AM EST - 1 year ago

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Jan 25, 2024, 7:00 AM EST - 1 year ago

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 16, 2023, 7:00 AM EST - 1 year ago

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:11 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 7:00 AM EDT - 1 year ago

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

Aug 14, 2023, 7:00 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

Jun 14, 2023, 9:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Jun 8, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

Jun 1, 2023, 4:20 PM EDT - 2 years ago

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

LAVA Therapeutics to Participate in the Jefferies Healthcare Conference

Jun 1, 2023, 8:09 AM EDT - 2 years ago

LAVA Therapeutics to Participate in the Jefferies Healthcare Conference

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Apr 11, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

Mar 9, 2023, 8:05 AM EST - 2 years ago

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

Feb 16, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

Feb 9, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

Feb 6, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

Jan 23, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

LAVA Therapeutics Announces Appointment of New Directors to the Board

Jan 6, 2023, 1:07 PM EST - 2 years ago

LAVA Therapeutics Announces Appointment of New Directors to the Board

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 10, 2022, 10:00 AM EST - 2 years ago

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Nov 16, 2022, 4:05 PM EST - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2022, 4:05 PM EDT - 2 years ago

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 3, 2022, 9:00 AM EDT - 2 years ago

LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

Nov 1, 2022, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

LAVA Therapeutics: Assessing A Promising Innovator

Oct 18, 2022, 2:32 AM EDT - 2 years ago

LAVA Therapeutics: Assessing A Promising Innovator

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Oct 7, 2022, 11:00 AM EDT - 2 years ago

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Sep 26, 2022, 8:00 AM EDT - 2 years ago

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Sep 13, 2022, 4:05 PM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 7, 2022, 7:41 AM EDT - 2 years ago

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

Jun 16, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

LAVA Therapeutics Announces Two Appointments to its Board of Directors

Jun 15, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Announces Two Appointments to its Board of Directors

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

Jun 2, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics Announces Annual Meeting of Shareholders

May 31, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Announces Annual Meeting of Shareholders

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

May 17, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

May 12, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

May 5, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 27, 2022, 10:05 AM EDT - 3 years ago

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting